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Abstract: Sphingosine-1-phosphate (S1P), via its G-protein-coupled receptors, is a signaling molecule
with important regulatory properties on numerous, widely varied cell types. Five S1P receptors
(S1PR1-5) have been identified, each with effects determined by their unique G-protein-driven
downstream pathways. The discovery that lymphocyte egress from peripheral lymphoid organs is
promoted by S1P via S1PR-1 stimulation led to the development of pharmacological agents which are
S1PR antagonists. These agents promote lymphocyte sequestration and reduce lymphocyte-driven
inflammatory damage of the central nervous system (CNS) in animal models, encouraging their
examination of efficacy in the treatment of multiple sclerosis (MS). Preclinical research has also
demonstrated direct protective effects of S1PR antagonists within the CNS, by modulation of S1PRs,
particularly S1PR-1 and S1PR-5, and possibly S1PR-2, independent of effects upon lymphocytes.
Three of these agents, fingolimod, siponimod and ozanimod have been approved, and ponesimod
has been submitted for regulatory approval. In patients with MS, these agents reduce relapse risk,
sustained disability progression, magnetic resonance imaging markers of disease activity, and whole
brain and/or cortical and deep gray matter atrophy. Future opportunities in the development of more
selective and intracellular S1PR-driven downstream pathway modulators may expand the breadth of
agents to treat MS.
Keywords: multiple sclerosis; sphingosine-1-phosphate modulators
1. Introduction
Although it was long thought that sphingosine, largely generated from hydrolysis of ceramides
within lysosomes [1,2], served primarily as a component of the structural sphingolipid family of
molecules, it is now recognized for its importance as a component of sphingosine-1-phosphate (S1P),
a crucial messenger molecule. S1P is generated by sphingosine kinase 1 or 2 (sk1, sk2), primarily
in red blood cells, platelets and endothelial cells [3,4] (Figure 1). Their G-protein-coupled receptors
are widely distributed in many organs and tissues, on cell surface plasma membranes, and on the
endoplasmic reticulum and cell nuclei, but it is cytoplasmic membrane-bound receptor sites that have
attracted the greatest attention [4]. Five S1P receptor (S1PR-1-5) subtypes have been identified [5,6]
(Figure 2a). The translational intracellular pathways activated by S1P-receptor (S1PR) interaction are
highly varied because of the multiplicity of receptor subtypes, the varied G-proteins to which they are
coupled, the multiple downstream pathways linked to G proteins, and the wide variety cells which
express S1PRs (Figure 2b; Table 1). Investigations into the physiological impact of S1P and its receptors,
as well as its potential contribution to disease pathogenesis, have revealed important opportunities for
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therapeutic interventions. This is particularly the case in the treatment of multiple sclerosis (MS). In the
past 10 years, three disease modifying therapies (DMT)s which modulate S1PRs, fingolimod (FGM),
siponimod (SPM), and ozanimod (OZM), have been approved for treatment of MS, and a fourth agent,
ponesimod (PNM) is under regulatory review.
The first part of this article describes the results of preclinical research, which has expanded
the knowledge of the physiological roles of S1P and its receptors, and a discussion of the specific
mechanisms of action of the S1PR modulators. This work did not only reveal important insights
into S1PR-based DMT mechanisms of action, but also widened the perspective on future therapeutic
opportunities for this class of molecules. The second part of this chapter summarizes the results of the
pivotal clinical trials of FGM, SPM, OZM, and the phase II and phase III trials of PNM upon clinical
efficacy, as well as the reported adverse events (AE) of these S1PR modulators.
Fingolimod (FGM) was the first S1PR modulator to be approved for the treatment of relapsing
forms of MS (RMS). Preclinical and clinical studies demonstrated that its use results in the sequestration
of lymphocytes, particularly central memory and naïve T and B cell lymphocytes in peripheral
lymphoid organs [7–11]. Pathological studies also demonstrated reduced pro-inflammatory cells
within the CNS following treatment with this class of agents, and it had been widely believed that the
sequestration of these potentially pro-inflammatory cells within lymphoid organs accounted for their
therapeutic efficacy in MS [7–10]. However, preclinical investigations, further detailed below, strongly
suggest that these agents may also act directly within the CNS, where there is an abundance of S1PR
expression, to ameliorate the impact of inflammatory disease.






knowledge  of  the  physiological  roles  of  S1P  and  its  receptors,  and  a  discussion  of  the  specific 
mechanisms of action of the S1PR modulators. This work did not only reveal important insights into 
S1PR‐based DMT mechanisms of  action, but  also widened  the perspective on  future  therapeutic 
opportunities for this class of molecules. The second part of this chapter summarizes the results of 
the pivotal clinical  trials of FGM, SPM, OZM, and  the phase  II and phase  III  trials of PNM upon 
clinical efficacy, as well as the reported adverse events (AE) of these S1PR modulators. 
Fingolimod (FGM) was the first S1PR modulator to be approved for the treatment of relapsing 
forms  of  MS  (RMS).  Preclinical  and  clinical  studies  demonstrated  that  its  use  results  in  the 
sequestration of lymphocytes, particularly central memory and naïve T and B cell lymphocytes  in 
peripheral  lymphoid  organs  [7–11].  Pathological  studies  also  demonstrated  reduced  pro‐
inflammatory cells within  the CNS  following  treatment with  this class of agents, and  it had been 
widely believed that the sequestration of these potentially pro‐inflammatory cells within lymphoid 




Figure  1.  Metabolic  Pathway  to  Sphingosine‐1‐phosphate  Synthesis  and  Migration  from  the 
Intracellular to Extracellular Space via Sphingosine‐1‐phosphate Transmembrane Transporters. 
  
Figure 1. Metabolic Pathway to Sphingosine-1-phosphate Synthesis and Migration from the Intracellular
to Extracellular Space via Sphingosine-1-phosphate Transmembrane Transporters.
Biomedicines 2020, 8, 227 3 of 23





Figure 2.  (A) Five G protein‐coupled Sphingosine‐1‐phosphate  receptors have been  identified.  (B) 
Each of the S1PRs is coupled to one or more G proteins, resulting in multiple different downstream 
messaging  targets  (See  Table  1).  S‐1‐P  =  Sphingosne‐1‐phosphate  (S‐1‐P),  S1PR  =  Sphingosine‐1‐
phosphate Receptor. 
















Figure 2. (A) Five G protein-coupled Sphingosine-1-phosphate receptors have been identified. (B) Each
of the S1PRs is coupled to one or more G proteins, resulti g in multiple different downstream messaging
targets (See Table 1). S-1-P = Sphingosne-1-phos ate (S-1-P), S1PR = Sphingosine-1-phosphate Receptor.
Table 1. G protein-coupled Sphingosine-1-phosphate receptor subset modulation of downstream
signaling pathways.
S1PR G Protein Downstream Signaling Pathways
S1PR 1–5 Gαi/o→ Akt→Ras→MAPK→Rac
S1PR 2–5 Gαq11→ DAG→PKC→Ca2+
S1PR 2 and 3 Gα12/13→ Rho→ROCK
S1PR = Sphingosine-1-phosphate Receptor, Akt = serine/threonine kinase (protein kinase B), Ras = small GTPase,
MAPK = mitogen-activated protein kinase, Rac = member of Rho family of small GTPases, DAG = Diacyl Glycerol,
PKC = protein kinase C, Rho = ras homolog gene family, ROCK = R o ki as .
2. Preclinical Studies
As noted above, S1P is a major intracellular signaling molecule via its G-protein-coupled membrane
bound receptors [12–15]. Because the S1PR subsets are coupled to different G-proteins, they can
modulate multiple downstream intracellular pathways (Table 1).
Although S1P is critically essential for normal CNS development and maturation [3,4,16,17] and
may regulate synaptic function [18], it may also be cytotoxic at elevated concentrations, such as when
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there is a genetic deficiency in its degradative enzymes, producing neuronal apoptosis [19–24]. S1P also
regulates calcium signaling [25], and may promote presynaptic calcium overload and cell death [26].
It is now known that S1P, through its interaction with S1PR-1, expressed on the surface of CCR7+
naïve, central memory B, and T cell lymphocytes, regulates the trafficking of these cells from peripheral
lymphoid organs [27–30]. The S1PR-1-expressing lymphocytes egress in response to the S1P gradient
(Figure 3). This effect of S1P makes its metabolic and translational pathways attractive potential
therapeutic targets for the treatment of cell-mediated immunologic disorders such as MS.
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Figure 3. The effect of Sphingosine-1-phosphate on lymphocyte mobilization from peripheral lymphoid
organs. Sphingosine-1-phosphate interaction with S1PR1-expressing lymphocytes over-rides CCR7-induced
retention signaling, which results in mobilization and egress of naïve and central memory lymphocytes
into circulation in response to the S-1-P gradient. Non-CCR7-expressing lymphocytes, such as effector
memory cells, are not S-1-P dependent for their entry into the peripheral circulation. B Cells = B cell
lymphocytes, T Cells = T cell lymphocyte, NK cells = natural killer cells, pDC Cells = plasmacytoid dendritic
cell, S-1-P = Sphingosine-1-phosphate, S1PR1 = Sphingosine-1-Phosphate Receptor, CCR7 = Chemokine
Receptor 7.
2.1. S1P Receptors
Fingolimod, approved for the treatment of relapsing forms of MS, is a non-selective S1PR
modulator, which once phosphorylated (FGM-P) by sk2 [31], has affinity for S1PRs 1, 3, 4, and 5 [7,31].
The interaction of FGM-P with the S1PR-1 on the surface of CCR7+ lymphocytes results in the
internalization and degradation of S1PR-1 [32,33] (Figure 4), promoting the sequestration of naïve,
central memory T, and central memory B cell lymphocytes in peripheral lymphoid organs [34].
The circulation of central effector B and T cells, which do not express CCR7, are unaffected by FGM-P.
When used in patients with relapsing forms of MS, FGM results in robust clinical and MRI evidence of
efficacy, in parallel with marked reduction in circulating B and T cell numbers.
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Figure 4. The effect of fingolimod-phosphate upon lymphocyte Sphinogosine-1-phosphate receptor-1.
Although initially acting as an agonist, sustained exposure of sphingosine-1-phosphate receptor
to fingolimod-phosphate results in receptor internalization and intracellular degradation. As a
consequence of sphingosine-phosphate receptor-1 internalization, CCR7-expressing lymphocytes are no
longer capable of responding to the sphingosine-1-phhosphate gradient. This results in naïve and central
memory cell retention in peripheral lymphoid organs. S1PR1 = Sphingosine-1-phosphate receptor-1.
It has been well-established that the CNS also expresses S1PRs, on neurons, astrocytes,
microglia, and oligodendroglia (OLG) during development, maturation, and adult cell states [35–37].
Furthermore, FGM-P, and the newer S1PR modulators SPM, OZM, and PNM, readily cross the
blood brain barrier (BBB), and are selectively accumulated within the CNS. Unlike FGM, these latter
3 agents do not req ire prior phosphorylation to be pharmacologically active. It is possible that
some of t therapeutic benefits of S1PR modulators result directly from their effects upon CNS
receptors, an in the discussion that follows, we present evidence that supports such a role for
these agents. Furthermore, there is evidence to suggest that the therapeutic effects of these agents
depends, at least in part, upon their interaction with CNS S1PRs [38].
The use of whole animal inflammatory CNS models, such as experimental allergic encephalitis
(EAE), non-inflammatory models of CNS demyelination using in situ cuprizone or lyolecithin, in whole
animal, brain tissue slice, and CNS cell culture models [39–42] have all provided important insights
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into fundamental S1P and S1PR physiology. They have also expanded knowledge of the mechanisms
by which S1PR modulation regulates CNS development [4,17], and may protect the CNS during
inflammatory insult [38]. What follows is a description of preclinical research which has provided
important insights into the role of selective S1PR subtypes, the effects of their modulation/inhibition,
and also the use of selective S1PR agonists and antagonists to further clarify the physiological roles of
these receptors, and their impact on inflammatory CNS insults.
Although multiple S1PRs are expressed in the mammalian CNS, S1PR-1, 2 and 5 have attracted
the most interest because of the pivotal roles they play in the development and myelinating function of
OLGs, the regulation of astrocytes and microglia, and in maintaining the integrity of the BBB.
2.1.1. S1PR-1
During CNS inflammation, both S1PR-1 and S1PR-3 are up-regulated by astrocytes and are
associated with astrocyte activation and increased production of glial acidic fibrillary protein (GFAP) [3].
The up-regulation of S1PR-1 is seen on activated GFAP-expressing astrocytes in or near active MS
lesions [43–45]. During active inflammation there is also S1PR-1-dependent up-regulation of microglia
(MGL) that is enhanced in the presence of S1P to further increase inflammation [46]. By contrast,
in EAE produced in astrocyte S1PR-1 knockdown mice, there is an inhibition of astrocyte activation [38].
Furthermore, selective S1PR-1 blockade enhances maturation of OLGs [40]. Thus S1PR-1 blockade is a
potentially important pharmacological target to reduce astrogliosis and promote remyelination in MS.
Although S1PR3 up-regulation occurs in activated astrocytes, the role of S1PR-3 in producing significant
cardiovascular effects, via its regulation of the KACh potassium channel [47–50], has diminished
interest in it as a target for modulation in MS.
2.1.2. S1PR-2
S1PR-2 is expressed on oligodendroglial progenitor cells (OPC) and macrophages (MPG) [51,52].
In mice with EAE, S1PR-2 activation promotes breakdown of BBB, which is prevented by the use
of selective endothelial cell S1PR-2 blocking agents [53], and in endothelial S1PR-2 knockout EAE
mice. In these latter models there is also an inhibition of fibrinogen extravasation into the CNS,
as well as the inhibition of MPG and MGL recruitment into CNS lesions [41]. To eliminate the
potentially confounding effects of systemic inflammation in EAE, models employing in situ injection of
lyolecithin-induced demyelination, have produced the same results: S1PR-2 knockout or pharmacologic
S1PR-2 inhibition reduced MCP and MGL infiltration of the lesions [41]. S1PR-2 is also a negative
regulator of oligodendroglial progenitor cell (OPC) maturation into OLGs. Following demyelination,
the inhibition of S1PR-2 promoted maturation of OPCs, increased re-myelination and increased the
number of mature myelinated axons [41]. In addition to being a receptor for S1P, S1PR-2 has a high
affinity for NOGO A, which also inhibits remyelination [54], providing a second S1PR-2 pathway for the
inhibition of re-myelination [55–57]. Consistent with these observations, the pharmacological inhibition
of S1PR-2, or use of S1PR-2 knockout mice, results in improved EAE scores, reduced BBB leakage,
less fibrinogen extravasation, reduced macrophage (MPG) and MGL recruitment, as well as increased
OLG accumulation and re-myelination [53]. Although not a target of any current clinically employed
S1PR modulators, S1PR-2 activation, because of its effects on BBB integrity, macrophage/MGL activation,
and myelination, could be an important potential therapeutic target of future drug development.
2.1.3. S1P Neurotropism and S1PR-1/S1PR-2 Synergy
Sphingosine-1-P, by stimulating both S1PR-1 and S1PR-2, may induce gene expression encoding
for the production of protective astrocyte neurotrophic factors, not achieved by S1PR-1 modulation
alone [58]. Bi-receptor S1PR-1 and S1PR-2 stimulation [59] appears to be necessary to up-regulate
neurotrophic mRNA expression, which only takes place in astrocytes [60,61]. To date there are no
pharmacological agents of which we are aware that operate jointly or exclusively at both S1PR-1 and
S1PR-2 under investigation as potential medications for MS, yet the importance of regulating astrocyte
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proliferation and astrogliosis would be reasons enough to examine agents that can synergistically
modulate both receptor subsets.
2.1.4. S1PR-5
The S1PR-5 is mainly expressed on OLGs in white matter tracts, and on brain endothelial
cells [51,62]. S1P5 receptor mRNA has been found primarily in the white matter of the CNS, but has
not been detected in neurons, microglia, or astrocytes [63,64]. S1PR-5 is expressed throughout the
development timeline of OLGs, from immature stages to the mature myelin-forming cell [62,65,66].
In mature OLGs, S1P5 receptors co-localize with myelin basic protein exclusively on myelinated axons
and not on OLG cell bodies [64].
Although S1P5 appears to mediate S1P-induced survival of mature OLGs, it may also induce
cell process retraction on immature OLGs [51,62], thus regulating a dual-signaling developmental
pathway. It appears that activation of S1PR-5 may be important in the maturation and survival of
OLGs by playing a role in their modulation, formation, and myelin repair [62].
As has been shown for S1PR-2, S1PR-5 influences BBB integrity and is highly expressed on human
brain endothelial cells. Studies have demonstrated that S1PR-5 plays a key role in BBB maintenance and
modulation of endothelial cell inflammatory state. S1PR-5 knockdown endothelial cells have reduced
barrier integrity [67]. Activation of S1PR-5 reduces the expression of inflammatory cell adhesion
molecules on their surface, and enhances the capacity of brain endothelial cells to prevent monocyte
penetration. It has been suggested [67] that the role of S1PR-5 may include induction of specific BBB
properties such as low paracellular permeability and increased expression of key brain endothelial
proteins such as tight junction, ATP binding cassette and glucose transporter molecules. These results
point out the potential importance of investigating pharmacological agents which have high affinity
and selectivity to promote S1PR-5 preservation in maintaining BBB integrity and protecting OLG
maturation and myelination.
2.2. Direct Pharmacological Actions of the S1PR Modulators in the CNS
Established and approved S1P agonists include fingolimod (FGM), siponimod (SPM),
and ozanimod (OZM). Ponesimod (PNM) has recently been submitted for regulatory approval
based upon Phase III clinical study outcomes. Because it has been available the longest, most data on
modulation of S1P receptors by these agents come from studies utilizing FGM. At low doses, FGM has
been shown to cause process extension of human OPCs via interaction with S1PR-1, but at high doses,
causes process retraction via S1PR-3 and S1PR-5 [42]. Furthermore, short-term FGM treatment causes
retraction and prevention of migration of OPCs via an S1PR-3 and S1PR-5-mediated pathway, whereas
long-term exposure led to increased cell survival via an S1PR-1-driven pathway [42,51]. Fingolimod
also enhances BBB integrity, probably by modulation of S1PR-5, reducing transendothelial migration
of monocytes in vitro, the latter being an initial step in the formation of new MS lesions [67].
2.2.1. Fingolimod
As noted above, the therapeutic effects of FGM appear to result at least in part from control of
lymphocyte trafficking via down-regulation of lymphocyte S1PR-1 (Figure 4) [68,69]. There is also
growing evidence from preclinical studies, that some of FGM’s therapeutic effects may be independent
of lymphocyte sequestration in peripheral lymphoid organs [38,69]. FGM readily crosses the BBB,
potentially enabling its subsequent modulation of S1PRs [35,69,70].
There is up-regulation of S1PR-1- and S1PR-3-expressing astrocytes [71] during active inflammation,
and there is growing evidence that astrocytes expressing S1PR-1 may be a primary FGM therapeutic target
in the CNS [72]. Consistent with this view has been the demonstration of diminished therapeutic benefit
of FGM in EAE in the absence of S1PR-1 expression on astrocytes in genetic knock down mice [38].
Fingolimod, which causes the internalization and destruction of astrocytic S1PR-1 [38] also
enhances remyelination in a number of different in vitro models and in EAE mice [40,45,73–75],
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prevents OLG death, reduces the number of reactive astrocytes and reduces the number of reactive MGL.
These beneficial effects are mimicked by the selective S1PR-1 antagonist CYM5442, which also prevents
the up-regulation of S1PR-1 on astrocytes [45]. As further evidence of the importance of the astrocyte
S1PR-1 receptor, the S1PR-1 gene is primarily expressed in astrocytes, its coupled-G-protein-regulated
pathway promotes astrocyte proliferation, and its selective blockade inhibits astrogliosis, potentially
reducing OLG death and demyelination. These results are supporting evidence that at least some of
the protective effects of FGM are mediated via S1PR-1 negative modulation in the CNS [45]. As further
support, deletion of the astrocyte S1PR-1 gene reduces production of the pro-inflammatory cytokines
IL-1β, IL-6 and IL-17, reduces demyelination, and eliminates any additive benefit of CNS protection by
FGM treatment [38].
2.2.2. Siponimod
Siponimod is a selective modulator of S1PR-1 and S1PR-5 [76,77], and was originally synthesized to
reduce cardiovascular effects by eliminating S1PR-3 affinity [78,79]. Its structure favors avid penetration
of the BBB. It has a short T1/2 elimination, and lymphocyte counts may return to baseline within 48 h of
the last dose (see Table 2) [78]. Recent studies in both human and rodent astrocytes have demonstrated
that SPM modulates cellular pro-survival pathways [80–82], primarily via S1PR-1 [82]. SPM also
demonstrates anti-inflammatory effects, reducing phosphatidyl choline, TNFα and IL-17-induced IL-6
production by via S1PR-1 modulation. In an in-situ injected curpizone mouse model, SPM treatment
reduces myelin breakdown-associated proteins, decreases the number of damaged axons, decreases
OLG loss, increases the number of myelinated axons, and reduces MPG and MGL infiltration [83].
In studies of EAE-induced excitotoxic synaptic degeneration, SPM treatment preserves gabaergic
neurons in the striatum, and reduces microgliosis, even in the absence of pro-inflammatory lymphocyte
affects. These results have been replicated in brain slices, further supporting a direct SPM affect
upon the CNS. It has been hypothesized that SPM, via its actions on S1PR-1, reduces MGL activation,
which in turn reduces pro-inflammatory lymphocyte recruitment into the CNS [83]. Lastly, since SPM
is also a modulator of S1PR-5, preservation of OLGs and myelinated axons in demyelination models
following its use is not unexpected. Although, to our knowledge, not yet reported, SPM may also
preserve BBB function via S1PR-5 modulation.
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11 days 6–8 h 30% of baseline 45% 30 days ***
ponesimod 21–33 h 2.5–5 h Not available 70% 4 days
* Increased by 50% in patients with moderate to severe heart disease, ** CC112273 the major ozanimod active
metabolite, *** 90% recovery to baseline lymphocyte count with 3 months.
2.2.3. Ozanimod
Ozanimod has a high affinity for S1PR-1 and to a lesser extent for S1PR-5. It selectively crosses the
BBB with brain to blood ratio of 10-16:1 [30] and its affinity for the S1PR-1 is comparable to FGM-P and
SPM [30]. Like FGM-P and SPM, it induces rapid internalization and degradation of S1PR-1 in rodents
and produces reduction in circulating B and T cell lymphocytes [30,84]. Compared to FGM and SPM,
there is more rapid lymphocyte reconstitution after it is discontinued. The t1/2 elimination of its major
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active metabolites, cc112273 and cc1084037, is only 11 days (see Table 2) [85]. Of note, OZM treatment
significantly improves EAE scores in mice, even in the presence of restored blood lymphocyte
counts [30], supporting a direct CNS therapeutic role. We are unaware of extensive preclinical studies
of OZM modulation of S1PR-5, its effects on OPCs, OLGs or myelination, or BBB integrity.
2.2.4. Ponesimod
Ponesimod is a selective S1PR-1 modulator [86,87], with a t1/2 elimination of 21-33 h [87], which like
FGM, SPM and OZM, reduces circulating B and T cell lymphocytes by up to 70%, with return to
baseline values within 4 days of cessation (see Table 2) [84,88–90], PNM readily crosses the BBB and
reduces EAE scores in mice [84].
3. Clinical Trial Results
3.1. Fingolimod
Fingolimod was the first oral medication, approved in patients with relapsing forms of MS.
The therapeutic efficacy of FGM for RMS was initially established in two pivotal, phase III, double-blind,
randomized clinical trials of adults, comparing FGM to placebo (FREEDOMS) and comparing FGM
to IFN-β-1a (TRANSFORMS). This was followed by the phase III extension studies FREEDOMS II
and extended TRANSFORMS. The regulatory approval for use of FGM in the treatment of RRMS in
children ages 10–17 years of age in 2018 [91] followed the results of the pivotal trial, PARADIGM [92].
3.1.1. FREEDOMS
FREEDOMS was a phase III double-blind, placebo-controlled trial with 1272 patients that
demonstrated superior efficacy of FGM in RMS when compared to placebo [93]. Inclusion criteria
included a diagnosis of RMS, Expanded Disability Status Scale (EDSS) score ≤5.5, and evidence of
active disease over the previous 2 years. The median disease duration was 6.7 years, and median EDSS
at baseline was 2.0. Patients were randomized in a 1:1:1 ratio to receive placebo, FGM 0.5 mg, or 1.25 mg
once daily. The primary endpoint was annualized relapse rate (ARR) and the main secondary endpoint
was time to three-month confirmed disability progression (CDP). Other secondary endpoints included:
time to first relapse, change in EDSS score and the MS Functional Composite (MSFC) z-score at baseline
compared to 24-months, conventional MRI measurements, drug tolerability, and safety. Because the
1.25 mg dose of FGM did not demonstrate therapeutic superiority to the 0.5 mg dose, it was the latter
that received regulatory approval, and for that reason only the data for the 0.5 mg dose are presented.
The ARR was 0.18 for 0.5 mg FGM, and 0.40 for placebo-treated patients (p < 0.0001), a relative
reduction of 54% in favor of FGM. Time to first relapse was significantly longer in FGM than in
placebo-treated patients and more FGM patients remained relapse free over 24-months. Cumulative
probability of three months of CDP was 17.7% for FGM and 24.1% for placebo (Hazard ratio 0.70).
During the 24-month study period, EDSS score and MSFC z-scores remained stable in the FGM-treated
group and minimally worsened in the placebo group. FGM treatment was associated with a significant
relative decrease in the number of new or enlarging T2 lesions (74%), gadolinium-enhancing (Gd+)
lesions (79%) and a relative reduction in brain volume loss (36%), all MRI comparisons being significant
at 24 months (p < 0.001).
3.1.2. TRANSFORMS
TRANSFORMS was a Phase III clinical trial, enrolling 1292 patients, comparing efficacy of FGM
to intramuscular IFNβ-1a in a 12-month, randomized, double-dummy, parallel group study in patients
with active RMS over the previous 24 months [94]. The inclusion criteria included a diagnosis of RMS,
EDSS ≤ 5.5. Patients were randomized 1:1:1 to oral FGM 0.5 mg or 1.25 mg once daily, or IFNβ-1a 30 µg
IM once weekly, and we only report on the FGM 0.5 mg vs. IFNβ-1a results. The primary endpoint
was ARR and major secondary endpoints included number of new or enlarging T2 MRI lesions at
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one year and 3-month CDP during the 12-month duration of the study. At 12 months, ARR was 0.16
for FGM, and 0.33 for IFNβ-1a patients (p < 0.001), a relative reduction in ARR of 52%. In the FGM
arm time to first relapse was longer and more patients remained relapse free than the IFNβ-1a treated
patients. FGM treatment was associated with a relative reduction in the mean number of new and
enlarged T2 lesions (FGM 1.7 and IFNβ-1a 2.6; p < 0.004), a 54% relative reduction in Gd+ lesions
(p < 0.001), a 31% relative reduction in percent brain volume loss from baseline (p < 0.001). In contrast,
there was no significant difference observed between the treatment arms with respect to 3 month CDP.
3.1.3. FREEDOMS II
FREEDOMS II, a phase III trial to evaluate the efficacy and safety of FGM [95] was a 24-month,
randomized, double-blind, placebo-controlled, evaluating the efficacy of FGM compared to placebo
in 1083 patients. Inclusion criteria included: a diagnosis of RMS, evidence of active disease over the
previous 24 months, and an EDSS ≤ 5.5. Patients were randomized in a 1:1:1 ratio to receive FGM
0.5 mg, or 1.25 mg, or placebo once daily but only the FGM 0.5 mg and placebo data are reported;
patients randomized to the FGM 1.25 mg arm were switched to 0.5 mg a day at the recommendation
of the data and safety committee. The primary endpoint of the trial was ARR. Secondary endpoints
included the effect of FGM upon time to 3-month CDP, change in MSFC score, and effect on MRI
measurements in comparison to placebo.
The ARR over 24 months was 0.21 for FGM and 0.40 for placebo (p < 0.0001), a relative reduction
of 48%. The percent change in brain volume from baseline to 24 months, was 0.9% for FGM and 1.3%
for placebo, a relative reduction of 31% (p < 0.001). The mean number of new and enlarged T2 lesions
at 24 months was 2.3 for FGM, and 8.9 for placebo, a relative reduction of 74%; there was a 70% relative
reduction in number of Gd+ lesions. There was no significant difference between FGM and placebo
in 3- or 6-month CDP. The time to first confirmed relapse was longer, and more patients remained
relapse-free in the FGM treated arm compared to placebo-treated patients at 24-months. MSFC scores
were also improved at month 24 in the FGM versus the placebo-treated arm.
3.1.4. Extended TRANSFORMS
Extended TRANSFORMS reported long-term results (up to 4.5 years) for the core TRANSFORMS
patients [96]. A total of 92% (n = 1027) of patients completing TRANSFORMS entered and 75.2%
completed the extension phase. Patients randomized to FGM 0.5 mg or FGM 1.25 mg in the core
study continued at the same dose in the extension study, whereas patients receiving IFNβ-1a were
re-randomized 1:1 to either FGM 0.5 mg or FGM 1.25 mg daily. Following the sponsor’s decision to
discontinue FGM 1.25 mg in 2009, all patients subsequently received FGM 0.5 mg until completion of
the extension phase. It is only the 0.5 mg FGM results vs. IFNβ-1a which are reported below.
The primary endpoint, ARR at 4.5 years, was significantly reduced in patients who initiated
FGM treatment in TRANSFORMS compared to those patients switching from IFNβ-1a to FGM during
Extended TRANSFORMS: (0.17 versus 0.27), a 35% relative reduction in risk of relapse (p < 0.001).
Patients initially treated with IFNβ-1a who switched to FGM, experienced a subsequent 50% reduction
in ARR, 0.4 to 0.2, by the end of the extension study. MRI outcomes in the extended TRANSFORMS
revealed a 63% reduction in new or newly-enlarged T2 lesion count in the group switching from
IFNβ-1a to FGM. The proportion of patients with no evidence of disease activity (NEDA: no relapses,
no MRI worsening, and no sustained disability progression) increased by 50% in the first year after
switching to FGM (43% to 66%). During the extension phase, there was no statistical difference in
the number of patients in either group who remained without Gd+ lesions. The relative reduction
in brain volume loss observed during the core study in patients continuously treated with FGM was
maintained through the extension study, whereas the patients switched from IFNβ to FGM experienced
a reduction in the rate of brain volume loss during the extension phase.
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3.1.5. PARADIGM
PARADIGM [92] was a 24 month randomized double-blind, active-controlled, parallel group
phase III study of 215 patients with RRMS between the ages of 10 and 17 years of age randomized to
either daily oral FGM (107) 0.5 mg (0.25 mg for those weighing 40 kg or less), vs. IFNβ-1a 30 µg IM
weekly. All patients had evidence of disease activity in the previous 2 years. The primary outcome,
ARR, was 0.12 in FGM versus 0.67 in the IFNβ-1a treated patients, a relative decrease of 82% (p < 0.001).
The mean percentage of relapse-free patients was 85.7 versus 38.8 favoring the FGM treatment arm.
Secondary outcomes included the total number of new and enlarged T2 lesions, which was 4.39 in
FGM versus 9.27 in IFNβ-1a treated patients, a 53% relative decrease (p < 0.001). The mean number of
Gd+ lesions/scan was 0.44 in FGM versus 1.28 in IFNβ-1a treated patients. The mean rate in brain
volume change was -0.48% in FGM versus −0.8% in IFNβ-1a treated patients.
3.2. Siponimod
As previously indicated, SPM is a selective S1P1R and S1P5R modulator that readily crosses the
BBB [78]. Preclinical studies indicate that it may preserve neurons by preventing excitotoxic synaptic
degeneration [83], enhancing cell survival pathways [80,82], and promoting remyelination in the
CNS [83]. Given the results of these preclinical studies, and because of the need to develop DMTs that
might slow disability worsening in patients with secondary progressive multiple sclerosis (SPMS),
it was decided to evaluate SPM efficacy in this patient population.
EXPAND
EXPAND [97] was a double-blind, randomized phase III study of 1645 adults, age 18–60, with SPMS
and an EDSS score of 3.0–6.5. Patients were assigned (2:1) to once daily oral SPM 2 mg or placebo for up
to three years, or until the occurrence of a pre-specified number of CDP events. The primary endpoint
was time to three-month CDP. At baseline, the mean time since first MS symptoms was 16.8 years and
time since conversion to SPMS was 3.8 years. Sixty-four percent of patients (n = 1055) had not had
a relapse in the previous two years; 56% (n = 918) needed walking assistance. Twenty-six percent
(288/1096) of patients receiving SPM and 32% (173/545) receiving placebo had three-month CDP
(hazard ratio 0.79, 95% CI 0.65–0.95), a relative risk reduction of 21% (p = 0.013). Of the secondary
endpoints, there was no significant difference between SPM and placebo-treated patients in the time to
three-month confirmed worsening of at least 20% in Timed 25 Foot Walk (T25FW). The increase in T2
lesion volume from baseline was significantly lower in SPM-treated versus placebo-treated patients,
with a between group difference of −695.3 mm3 (95% CI –877.3 to –513.3; p < 0.0001). Numerically more
patients receiving SPM were free of Gd+ lesions (89% vs. 67%) and of new or enlarging T2 lesions
(57% vs. 37%) than their placebo-treated counterparts. Siponimod was approved for the treatment of
“active forms” of SPMS, defined as patients having had a relapse in the previous 2 years, because this
was the only subgroup in which the primary end-point was achieved. Following completion of the
core EXPAND trial, an open label extension was initiated which is expected to conclude in 2024.
3.3. Ozanimod
Ozanimod, a S1PR1 and S1PR5 modulator, that has been studied in two phase III clinical trials,
RADIANCE Part B and SUNBEAM, the most recent agent in this class to receive regulatory approval.
Each of these trials was a randomized, double-blind, double-dummy, parallel group, active-controlled
study, evaluating the efficacy and safety of daily oral OZM 0.5 mg or 1 mg versus weekly IFNβ-1a
30 µg IM in patients with RRMS. Following its ingestion, OZM is partly transformed into 2 primary
metabolites, CC112273 and CC1084037, which account for the bulk of OZM pharmacological effects,
each with a t1/2 elimination of approximately 11 days, compared to 19–22 h for OZM itself [85].
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3.3.1. RADIANCE Part B
RADIANCE Part B [98], a 24 month trial, included 1,313 patients with RRMS randomized to daily
oral OZM 0.5 mg (n = 439), OZM 1 mg (n = 433) or weekly IFN β-1a 30 µg IM (n = 441). Inclusion criteria
were ages 18–55 years, EDSS 0.0–5.0, diagnosis of RRMS, and evidence of active disease over the
prior 24 months. Exclusion criteria included recent myocardial infarction, TIA, stroke, prolonged QTc
interval, resting heart rate < 55 bpm, Type I diabetes, or uncontrolled Type II diabetes.
The primary endpoint in RADIANCE Part B was ARR at each OZM dose versus interferon β-1a
over 24 months of treatment. Key secondary endpoints included number of new or enlarging T2
brain lesions, number of Gd+ brain lesions, and time to three-month CDP. Other secondary endpoints
included relative rate of whole brain volume loss. Exploratory outcomes included relative changes
in cortical grey matter and thalamic volumes over the 2 years of observation. Because of its superior
efficacy, regulatory approval was only given the 1.0 mg dose. The 0.5 mg data are not presented.
ARR at two years was 0.172 for OZM and 0.276 for IFN β-1a, a relative reduction of 38% favoring
OZM (p < 0.0001). There was a 42% relative reduction in new and enlarging T2 lesions with OZM
treatment compared to IFNβ-1a (p < 0.001). The relative reduction in number of Gd+ enhancing brain
lesions at two years was 53% in OZM-treated patients (p = 0.0006) compared to patients treated with
IFNβ-1a. There were no statistically significant differences between OZM and IFNβ-1a treatment in
time to three-month CDP. Relative reduction in brain volume loss at 2 years was 27% less in OZM
(p < 0.0001) than in IFNβ-1a treated patients. Relative cortical gray volume loss was reduced by 58%
in patients treated with OZM (p < 0.0001) and relative thalamic volume loss at 2 years was reduced by
32% (p < 0.0001) in patients receiving OZM.
3.3.2. SUNBEAM
The SUNBEAM phase III study [99] included 1,346 patients with RRMS, randomized to daily oral
OZM 0.5 mg (n = 451) or 1 mg (n = 447) versus weekly intramuscular 30 µg IFNβ-1a IM (n = 448).
Inclusion criteria included ages 18–55 years, EDSS 0.0–5.0, diagnosis of RRMS, with the same remaining
inclusion and exclusion criteria as RADIANCE Part B. Only the data for 1 mg OZM is presented.
The primary endpoint in SUNBEAM was ARR with OZM treatment versus IFNβ-1a over
12 months of observation. Key secondary endpoints included number of new or enlarging T2 brain
lesions, number of Gd+ brain lesions at one year, and time to three-month CDP. Other secondary
endpoints included whole brain volume loss. Exploratory endpoints included cortical grey matter
and thalamic volume changes at one year. ARR at one year was 0.181 for OZM and 0.35 for IFNβ -1a
treated patients, a relative risk reduction of 48% (p < 0.0001) favoring OZM treated patients. There was
a 48% relative reduction in the number of new or enlarging T2 brain lesions favoring OZM-treated
patients (p < 0.001) and total number of Gd+-brain lesions reduced by 63% in the OZM treatment arm
(p < 0.0001) compared to IFNβ-1a. There was no statistically significant difference between OZM and
IFNβ-1a for time to three-month CDP. There was a 33% relative reduction (p < 0.0001) in percentage
whole brain volume decrease for OZM treated patients, as well as an 84% (p < 0.0001) relative reduction
in cortical grey matter loss and a 39% (p < 0.0001) relative reduction in thalamic volume loss in OZM
treated patients. It is of particular interest to learn the results of on-going studies which are focused on
cognitive functioning and patient reported outcome status [100] in light of the demonstrated relative
reduction in cortical gray matter and thalamic volume loss in OZM treated patients.
The regulatory approval for the higher OZM dose is a 92 mg capsule, as opposed to the 1.0 mg
OZM hydrochloride tablets used in the clinical trials [85].
3.4. Ponesimod
Ponesimod (PNM), a selective S1PR-1 modulator without known effect on the remaining four
S1PRs, has been studied in one phase III clinical trial.
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OPTIMUM
OPTIMUM [101], was a 108 week multicenter, randomized, double-blind, parallel group, and active
controlled study, evaluating the efficacy, safety, and tolerability of daily oral PNM 20 mg versus daily
oral teriflunomide (TFM) 14 mg in adults with RRMS. OPTIMUM enrolled 1,133 patients, randomized
to receive PNM (n = 567) or TFM (n = 566). Inclusion criteria included ages 18 to 55 years, EDSS 0.0-5.0,
diagnosis of RRMS, and active disease in the 24 months prior to screening. The primary end-point
was ARR over 108 weeks. Key secondary end-points included change from baseline to week 108 in
fatigue-related symptoms, as measured by the symptoms domain of the FSIQ-RMS. Other secondary
endpoints included the mean number of combined unique active lesions (CUAL) per year, defined as
new Gd+1 lesions and any new or enlarging T2 lesions. In addition, time to 12-week and 24-week
CDP was also determined.
There was a 30.5% relative reduction (p = 0.0003) in ARR in PNM treated patients (0.202 versus
0.290) compared to TFM treated patients. Ponesimod demonstrated superior improvement in fatigue
scores at week 108 compared to TFM as measured by the FSIQ-RMS weekly symptom score (mean
difference −3.57, p = 0.0019). There was a 56% relative reduction in CUALs per year (1.405 versus 3.164)




In FREEDOMS, 94% of patients receiving FGM compared to 93% of patients receiving placebo had
an AE. The majority of these events were mild to moderate with 7.5% of patients on FGM stopping due
to side effects compared to 7.7% on placebo. In TRANSFORMS, 86% of FGM 0.5 mg patients compared
to 92% of patients on IFNβ-1a had an AE. However, 6% of patients on FGM versus 4% or patients on
IFNβ-1a discontinued due to an AE [93,94].
In FREEDOMS, overall, incidence of infections was the same in all treatment groups;
however, lower respiratory infections were more common in patients receiving FGM. There were
two deaths in the 1.25 mg FGM group, one each of disseminated primary varicella zoster and herpes
simplex encephalitis. The overall rate of herpes infections receiving FGM was 0.01 (10/854) and
0.01 (4/418) in placebo treated patients. As of this writing, there have been 36 confirmed cases of
PML in greater than 746,700 patient years since FGM approval. In an analysis of 21 PML cases, age at
treatment initiation was not a risk factor for the development of PML; however, longer duration
of exposure to FGM increased the risk of developing PML [102]. As of February 2019, 46 cases of
cryptococcal infections have been reported. (Novartis data on file), the majority of whom were
treated for 2 or more years
Macular edema was slightly more common in patients on 0.5 mg of FGM compared to placebo,
0.5 verses 0.4%, and typically occurred within the first 3 to 4 months of therapy. Because patients with
diabetes and uveitis are at higher risk of developing macular edema, they were excluded from the
clinical trials. Given the risk of macular edema, a baseline eye exam is recommended within 6 months
of starting and then 3 to 4 months after beginning FGM [91].
Fingolimod, on average, lowered the heart rate by eight beats per minute. Following the first
dose, 0.6% of patients receiving FGM developed symptomatic bradycardia compared to 0.1% in the
placebo group, with rare cases of second degree AV block reported. Nonetheless, patients are required
to undergo an ECG prior to the first dose observation (FDO), and then at least a 6 h FDO, during which
time hourly pulse and blood pressure are obtained, followed by an additional ECG at the end of
monitoring. Medications which can cause bradycardia or prolong the QT interval, such as beta blockers.
Selective serotonin and norepinephrine reuptake inhibitors are to be used with caution and may prompt,
overnight or more prolonged ambulatory cardiac rhythm monitoring. Fingolimod is contraindicated in
patients with recent myocardial infarction, unstable angina, stroke, transient ischemic attack, or heart
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failure within the last 6 months [91]. There was also an average 3 mm Hg increase in systolic blood
pressure and 2 mm Hg increase in diastolic pressure in patients on FGM. Elevation in liver enzymes
was more commonly seen in the patients receiving FGM, with elevations of three times the upper
limit of normal (ULN) or greater were seen in 14% of patients treated with FGM and in 3% of patients
on placebo, typically occurring within 6 to 9 months of starting FGM. Peripheral lymphocyte counts
dropped by 73% on average in patients receiving FGM, and typically return to baseline values 1–2
after stopping FGM (Novartis data on file). To date, there has been no evidence that lower lymphocyte
counts are predictive of increased infection risk [103].
Skin cancer, particularly basal cell carcinoma, may be more common in patients on FGM [91].
Post-marketing studies have also reported rare cases of cutaneous melanoma and squamous cell
carcinoma [104,105].
In the pediatric population (PARADIGM), the incidence of AEs was 88.8% in FGM and 95.3% in
IFNβ-1a treated patients. The most common side effects in the FGM treated patients were headache
(31.8%), viral upper respiratory infections (21.5%), Upper respiratory infections (15.9%), leukopenia
(14%), influenza (1.2%), cough (9%), and pyrexia (7.5%). Serious AEs occurred in the FGM treated
cohort and 4.7 % of FGM treated patients discontinued the trial because of SAEs. These AEs included
convulsions (5.6%), and 3.7% of patients had serious infections, including one case each of appendicitis,
cellulitis, oral abscess, and viral pharyngitis. Single SAE cases also included agranulocytosis, arthralgia,
auto-immune uveitis, gastrointestinal necrosis, vasculitis, second degree AV conduction block, and small
bowel obstruction.
Fingolimod is not recommended during pregnancy and lactation, based upon its teratogenicity,
increased fetal loss and its presence in the milk of lactating animals. Prescribing information currently
recommends stopping FGM 3-months prior to planning conception; however this recommendation
may require revision in light of recent reports of increased MS breakthrough activity, occurring in
10–25% of patients within 12 weeks of discontinuing FGM [106,107]. Patients with a higher annualized
risk of relapse or higher EDSS prior to starting FGM may be at greater risk of rebound disease once
stopping FGM [108].
4.2. Siponimod
The SPM safety profile is similar to that of FGM. In EXPAND [97], 89% of patients receiving SPM
and 82% of patients receiving placebo had an AE. Non-serious adverse events leading to discontinuation
in the study was 4% versus 3% respectively. Serious adverse events occurred in 18% of the SPM group
compared to 15% in the placebo group.
Rate of infections were also similar in both groups, but upper and lower respiratory infections,
as well as herpes zoster reactivation, were more common in the SPM treated group. The risk of herpes
infection was 2.5% in SPM versus 0.7% in placebo treated patients. No cases of PML or cryptococcal
infections were reported, although these opportunistic infections may emerge as larger populations are
treated for longer durations, given the similar mechanism of action compared to FNM. The reduction
in the peripheral lymphocyte count was between 20 to 30% which is less than that observed in
patients treated with FGM [93,94], but whether this impacts the comparative rate of infection is yet to
be determined.
Liver function abnormalities were observed in 10.7% of SPM treated patients and 3.7% in the
placebo group.
Rate of macular edema was 1.8% in patients on SPM and 0.2% of patients treated with placebo.
This is higher than 0.4% reported in the phase III clinical trials with FGM [93,94].
Seizures occurred in 1.7% of SPM treated patients and was 0.4% in the placebo group.
The reduction in heart rate was a mean of six beats per minute in the SPM treated group, with the
maximum reduction occurring on average 4 h after the first dose. Bradycardia was reported as an
AE in 6% of patients receiving SPM compared to 3% receiving placebo. Cases of Mobitz type II or
higher degree atrio-ventricular (AV) block were not observed. As a result, first dose observation is not
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required except for patients with recent history of myocardial infarction, unstable angina, recent stroke,
TIA or baseline heart rate of less than 55 beats per minute [109]. Clinicians may also recommend first
dose observation for patients on medication which may lower heart rate, particularly those medication
that slow AV conduction.
Elevation in liver enzymes was 10.1% in patients on SPM, versus 3.7% of patients on placebo.
Overall, rate of malignancies was the same in each group.
Medications which inhibit the hepatic enzymes CYP2C9 and CYP3A4 can result in elevated
concentration of SPM, and the opposite is true for hepatic enzyme inducers. Furthermore, in patients
with the CYP2C9 genotype variants CYP2C9 1*/3* or 2*/3* should receive only 1.0 mg a day maintenance
dosing and those with the 3*/3* genotype should not receive SPM at all due to their inhibition of SPM
degradation in the liver [109].
4.3. Ozanimod
In RADIANCE and SUNBEAM, overall AEs and AEs leading to discontinuation were lower in
both groups of patients taking OZM compared to interferon beta-1a. Nasopharyngitis, elevated liver
enzymes, hypertension, and urinary tract infections were commonly seen in the OZM groups in both
clinic trials. No serious opportunistic infections were reported, and the rate of herpes infections were
the same across the three treatment groups.
There was one case of posterior reversible encephalopathy syndrome (PRES) in a patient receiving
1.0 mg OZM, occurring 10 months after starting the medication. Of note, post-approval cases have also
been reported in patients treated with FGM [110,111]. Mean absolute lymphocyte count in patients on
OZM 1.0 mg were reduced by approximately 45% by 3 months, and maintained at that level thereafter.
The rate of macular edema was 0.3% in each OZM and the IFNβ-1a group. Maximum mean reduction
in heart rate on day 1 was 0.6 bpm at 5 h in RADIANCE. Four patients treated with OZM had a
heart rate less than 45, but had baseline heart rates of 55-64 bpm, and no symptoms were reported.
In SUNBEAM, the maximum mean reduction was 1.8 bpm at 5 h, with no rate below 45 bpm reported.
No second- or third-degree heart block was observed in either study. Given the minimal reduction in
heart rate, FDO is not required for most patients.
As with the other S1PR-1 modulators, mild elevations in liver function enzymes were observed.
In RADIANCE, 6.7% of patients on 1.0 mg of OZM had an ALT of 3 X ULN normal, as did 3.9% of
patients on IFNβ-1a. In SUNBEAM, the rate was 4.3% for OZM and 2.2% for IFNβ-1a treated patients.
4.4. Contraindications and Cautions
The use of FGM, SPM, and OZM is contraindicated in patients with recent (within the past
6 months) myocardial infarction or stroke, unstable angina, class III/IV heart failure4.4, recent transient
ischemic attack and in patients receiving class I and Class III anti-arrhythmics, patients with Mobitz
type 2 s or third degree heart block, sino-atrial block, or sick sinus syndrome without a functioning
pacemaker. In addition, specifically for OZM there is a contraindication for the concomitant use of
monoamine oxidase inhibitors and in patients with untreated severe sleep apnea. The concomitant use
of SSRIs, SNRIs and narcotics is not recommended for any of the S1PR modulators [85,91,109].
4.5. Ponesimod
The proportion of patients experiencing at least one treatment emergent AE (TEAE) in OPTIMUM
was similar for both PNM and TFM, although discontinuation due to TEAE was higher in the PMN
than the TFM group, 8.7% vs. 6.0% respectively. Premature discontinuations due to elevated liver
enzymes and respiratory events were relatively higher in the PNM than TFM groups. The most
common AEs of special interest were elevated liver function tests in the PNM group, (22.7% vs. 12.2%),
hypertension (10.1% vs. 9.0%), and pulmonary events (8.0% vs. 2.7%). Most ALT increases ≥3X
ULN were single transient asymptomatic events that spontaneously resolved on treatment or resulted
Biomedicines 2020, 8, 227 16 of 23
in protocol mandated discontinuation. Eight seizures were reported in patients treated with PMN
compared to one patient on TFM.
Skin malignancies occurred in five patients treated with PMN and in one patient in the TFM
group. Four cases of bradycardia (0.7%) occurred in the PMN 20 mg group and an additional three
patients experienced first degree atrioventricular block. None of the events were serious or led to
treatment discontinuation.
5. Potential Therapeutic Opportunities
As is evident from the data presented, the S1PR modulators are an important addition to the list of
DMTs for the treatment of MS. In addition to their oral route of administration, an important addition
to patient quality of life, with a higher likelihood of compliance and persistence, they offer significant
improvement in clinical efficacy at acceptable levels of risk in studies in which they have been compared to
“platform” injectable or oral therapies. Important questions and research opportunities remain. Will agents
with more potent S1PR-5 modulation improve remyelination, as a result of improved maturation of OPCs
and enhanced myelin formation by OLGs? Will their use reduce inflammatory impact of MS by the
enhancement of BBB integrity? Will selective S1PR-2 inhibition stimulate remyelination by blocking the
NOGO/LOGO membrane complex, and will simultaneous S1PR-1 and S1PR-2 provide greater synergistic
regulation of astrocytes than either agent alone? Since S1PR-3 is up-regulated on astrocytes during
CNS inflammation [112] can CNS selective S1PR-3 modulators be developed which do not also increase
cardiovascular side effects? Lastly, as more is learned about the intracellular pathways activated or
inhibited by S1P and its receptors, the development of pharmacological agents which can manipulate these
pathways, and the development of agents that can interact with intracellular S1PRs, offer highly specific,
potentially fruitful therapeutic opportunities for MS and numerous other diseases, including rheumatoid
arthritis [113–115], systemic lupus [116,117], polymyotisis [118], ulcerative colitis [119], psoriasis [120],
colon cancer [121–123], breast cancer [124–126], lung cancer [127,128] and atherosclerosis [129,130].
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